Introduction
Erectile dysfunction has been described as the persistent inability to achieve and/or maintain an erection sufficient for satisfactory sexual activity'. According to the Massachusetts Male Aging Study, erectile dysfunction may affect up to 18 million American men 40 to 70 years old2 and should be considered a major health concern. In addition to age, important risk factors for erectile dysfunction include heart disease, hypertension, diabetes, cigarette smoking, spinal cord injury and surgery of the pelvic region.
Penile erection is a haemodynamic response. Increased blood flow into the trabecular spaces of the corpora cavernosa occurs as a consequence of the relaxation of the corpus cavernosum and associated arteries3. There is increasing evidence that nitric oxide (NO) has a key role in mediating penile erection. Following sexual stimulation, NO is released from non-adrenergic, non-cholinergic nerves within the penis to activate guanylate cyclase. Following stimulation of guanylate cyclase the formation of cyclic guanosine monophosphate (cGMP) is increased mediating a relaxation of the corpus cavernosum and penile arterioles4. Intracellular levels of cGMP are controlled by a balance between its formation and degradation via cyclic nucleotide phosphodiesterase (PDE) isozymes. Phosphodiesterase type 5 (PDE5) is the pre-dominant isozyme responsible for the metabolism of cGMP in the corpus cavernosum5. Thus, inhibition of this enzyme represents a new target for the treatment of erectile dysfunction.
Sildenafil ( Figure 1 ) is a novel inhibitor of PDE5 which has been shown to be an effective oral treatment of erectile dysfunction. This paper describes the pre-clinical pharmacology of sildenafil. 
In vitro Profile
Sildenafil potently inhibited PDE5 expressed in the corpus cavernosum (Table 1 ) and it was selective over PDE I (80-fold), PDE2 (>I 9,000-fold), PDE3 (>4,600-fold), PDE4 (2,000-fold) and PDE6 (10-fold). The inhibition of PDE5 by sildenafil has been shown to be competitive in nature 6. As a consequence of the inhibition of PDE5, sildenafil increased the levels of cGMP in the rabbit corpus cavernosum' and cultured human corpus cavernosum smooth muscle cells8. Table 1 Effects of sildenafil on the activities of human nhosnhodiesterase i
In the absence of NO-drive sildenafil had no effect on phenylephrine-contracted rabbit corpus cavernosum. However, it enhanced the relaxant effect of sodium nitroprusside. Thus, the concentrations of sodium nitroprusside which relaxed the rabbit corpus cavernosum was reduced from 6.15 µM in the absence of sildenafil to 4.94 µM in the presence of sildenafil 10 nM. Higher concentrations of sildenafil caused a further potentiation of sodium nitroprusside ( Table 2 ). These data demonstrate that sildenafil acts to potentiate the effects on NO drive in the corpus cavernosum. Table 2 The effects of sildenafil on the relaxation of phenylephrine (10 4M)-contracted rabbi isolated corpus cavernosal strips induced by sodium nitroprusside (SNP). Results an (95% Confidence Interval, LL" s for SNP (tM) (n=7-10).
The ability of sildenafil to potentiate the effects of NO is also observed in other tissues, such as isolated vascular preparations. Consistent with that observed on the rabbit corpus cavernosum, in the absence of NO-drive, sildenafil had no effect on phenylephrine-induced contractions of the rabbit aorta. However, a combination of sildenafil and glyceryl trinitrate increased the concentration of phenylephrine required to contract the rabbit aorta by 50% of the maximum response from 0.33 pM to 6.85 µM (Table 3) . Therefore sildenafil will potentiate the effects of NO on vascular beds other than the corpus cavernosum. Table 3 Effects of sildenafil and glycce yl trinitrate (GTN) alone and in combinati contractile responses of rabbit isolated aortic rings to nhenvlenhrine_ (n= PDE3
or no effect on isolated cardiac tissue. To investigate this further, the effects of sildenafil, in comparison with milrinone, on the isolated dog trabeculae cameae has been studied. Milrinone-induced a concentration related increase in contractility of the electrically stimulated (1 Hz, 2-5 msec, voltage 10% above threshold) dog isolated trabeculae carneae (Table 4 ). In contrast, sildenafil had no effect even at concentrations 1000-fold higher than those active on the rabbit isolated corpus cavernosum. Thus sildenafil is devoid of direct inotropic effects on isolated cardiac tissue. Table 4 Effects of sildenafil and milrinone on the contractility of electrically-ad isolated trabeculae. (n=7).
In vivo Profile
An injection of sodium nitroprusside in to the corpus cavernosum of the anaesthetised dog induced a small rise in intracavernosal pressure (Figure 2 ). Intravenously administered sildenafil had no effect on intracavernosal pressure when given alone, but potentiated, in a dose-related manner (ED50 16.2 .tg/Kg), the effects of sodium nitroprusside. These effects were observed in the absence of meaningful effects on blood pressure. A similar effect of sildenafil on changes in intracavernosal pressure induced by stimulation of the pelvic nerve has also been demonstrated in the doe. The plasma concentrations of free drug achieved in these studies following efficacious doses of sildenafil were approximately 2 nM9. PDE6 is expressed in the retina and has an important role in phototransduction. Thus, upon absorption of light, rhodopsin, the visual pigment of the rod, stimulates PDE6 via the G-protein, transducin10. The consequent increase in hydrolysis decreases the concentration of cGMP, leading to closure of the cGMP-gated ion channel and hyperpolarisation of the photoreceptors. The characteristic changes in electrical potential in the retina can be measured via surface corneal electrodes in the form of the electroretinogram which consists of several electrical potentials of known origin". The photoreceptors (rods and cones) hyperpolarise in response to light giving rise to the initial negative, a-wave, of the ERG. The positive b-wave reflects the subsequent depolarisation of the post synaptic Miiller and bipolar cells. The effects of intravenously-administered sildenafil on the ERG response to a flash of blue light was studied in the dark-adapted anaesthetised dog. Plasma concentrations of sildenafil which were efficacious on the corpus cavernosum had no effect on the ERG (Figure 3) . Higher concentrations (100 to 1000 nM) caused a dose-related increase in the implicit time of the a-wave and b-wave and reduction in the amplitude of the a wave of the ERG. These effects were fully reversible and returned to pre-treatment values in a manner consistent with the plasma half life in the dog. Importantly, in long term toxicology studies, there was no change in the structure of the retina of animals exposed to these concentrations of sildenafil which were active on the ERG". The ability of high doses of sildenafil to modify the ERG response to a flash of light is consistent with inhibition of PDE6 and probably accounts for the low incidence of visual adverse events observed in clinical trials with sildenafil. 
Conclusions
In conclusion, sildenafil has been shown to be a potent and selective inhibitor of PDE5. Although the compound has little direct effect on the corpus cavernosum it potently enhanced the relaxant effects of nitric oxide both in vitro and in vivo. The selectivity of sildenafil over key phosphodiesterase enzymes has also been confirmed in functional tests. Thus, sildenafil had no effect on the dog trabeculae carneae and therefore has no direct inotropic effect. Furthermore, the functional selectivity of sildenafil for PDE5 compared with PDE6 has also confirmed in the anaesthetised dog. Plasma concentrations which were active on the corpus cavernosum had no effect on the ERG evoked by a flash of blue light in the dog. These data suggest that the low incidence of visual adverse events observed with high doses of sildenafil in patients with erectile dysfunction are mediated through inhibition of PDE6.
Overall, the pre-clinical pharmacology of sildenafil has confirmed that the compound is a potent and selective PDE5 inhibitor useful in the treatment of erectile dysfunction.
